Finance

Lists
Why is MAZE down 3,37%?
Dive Deeper
MAZE:NASDAQ
Maze Therapeutics Inc
25,36 USD
-3,37%
(-0,89) 1D
8-окт., 11:51:30 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MAZE...
Open
25,97 USD
High
26,44 USD
Low
25,14 USD
Mkt. cap
1,41 млд
Avg. vol.
756,05 миң
Volume
128,59 миң
52-wk high
53,65 USD
52-wk low
21,95 USD
EPS
-2,51 USD
Shares outstanding
55,55 млн
No. of employees
141
Open
25,97 USD
High
26,44 USD
Low
25,14 USD
Mkt. cap
1,41 млд
Avg. vol.
756,05 миң
Volume
128,59 миң
52-wk high
53,65 USD
52-wk low
21,95 USD
EPS
-2,51 USD
Shares outstanding
55,55 млн
No. of employees
141
News stories
From web sources and news partners
About Maze Therapeutics Inc
CEO-
Employees141
Founded2017
HeadquartersЮг Сан Франциско, Калифорния, Америка Кошмо Штаттары
SectorPharmaceutical industry
Websitemazetx.com
Analyst ratings
Based on 7 analysts giving stock ratings to MAZE in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for MAZE in the last 3 months.
Highest
Current 25,36 USD
110,00 USD (+333,67%)
Average
61,43 USD (+142,18%)
Lowest
46,00 USD (+81,35%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
110,00 USD
+333,7%
10/05/2026
Laura Chico
Wedbush
Buy
Maintained
48,00 USD
+89,2%
09/23/2026
Julian Harrison
BTIG
Buy
Maintained
46,00 USD
+81,4%
09/22/2026
Eric Joseph
Citi
Buy
Initiated
50,00 USD
+97,1%
09/23/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
57,00 USD
+124,7%
09/22/2026
Danielle Brill
Truist Financial
Buy
Maintained
64,00 USD
+152,3%
09/22/2026
Sadia Rahman
Wells Fargo
Buy
Maintained
55,00 USD
+116,8%
09/09/2026
Salim Syed
Mizuho Securities
Buy
Maintained
97,00 USD
+282,4%
06/23/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
53,00 USD
+108,9%
05/22/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/12/2026
Martin Auster
Raymond James
Buy
Reiterated
56,00 USD
+120,8%
03/25/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
50,00 USD
+97,1%
03/25/2026
Debjit Chattopadhyay
Guggenheim
Buy
Reiterated
58,00 USD
+128,7%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
20,00 млн
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
25,19 млн
27,57 млн
34,15 млн
34,94 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,78 млн
10,49 млн
12,40 млн
13,10 млн
Operating expense
32,96 млн
38,06 млн
46,55 млн
48,04 млн
Total operating expenses
32,96 млн
38,06 млн
46,55 млн
48,04 млн
Operating income
-32,96 млн
-38,06 млн
-26,55 млн
-48,04 млн
Other non operating income
-
-
-
-
EBT including unusual items
-30,09 млн
-34,57 млн
-24,21 млн
-44,73 млн
EBT excluding unusual items
-30,09 млн
-34,57 млн
-24,21 млн
-44,73 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-30,09 млн
-34,57 млн
-24,21 млн
-44,73 млн
Net profit margin
-
-
-121,04%
-
Earnings per share
-0,66
-0,65
-0,45
-0,76
Interest and investment income
2,88 млн
3,49 млн
3,21 млн
4,24 млн
Interest expense
-
-
-866,00 миң
-931,00 миң
Net interest expenses
2,88 млн
3,49 млн
2,34 млн
3,31 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-32,39 млн
-37,56 млн
-26,11 млн
-47,64 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору